Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia.
Publication
, Journal Article
Mourad, A; Fowler, VG; Holland, TL
Published in: Clin Microbiol Infect
August 2023
We propose a two-stage clinical trial in patients with Staphylococcus aureus bacteremia (SAB). In Stage 1 we will evaluate metagenomic next generation sequencing from blood as a quantitative biological surrogate for clinical endpoint in patients with SAB, similar to quantitative HIV viral load in HIV-infected patients. In Stage 2, we will conduct a randomized controlled trial to individualize duration of antibiotic therapy for based upon the presence of S. aureus genetic material in patients’ blood. The proposed study addresses two critical aspects of treatment of patients with SAB: the identification of a surrogate biological endpoint for future clinical trials, and a new approach by which to individualize patient management.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Microbiol Infect
DOI
EISSN
1469-0691
Publication Date
August 2023
Volume
29
Issue
8
Start / End Page
955 / 958
Location
England
Related Subject Headings
- Staphylococcus aureus
- Staphylococcal Infections
- Microbiology
- Methicillin-Resistant Staphylococcus aureus
- Humans
- High-Throughput Nucleotide Sequencing
- Bacteremia
- Anti-Bacterial Agents
- 3207 Medical microbiology
- 3202 Clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mourad, A., Fowler, V. G., & Holland, T. L. (2023). Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia. Clin Microbiol Infect, 29(8), 955–958. https://doi.org/10.1016/j.cmi.2023.04.004
Mourad, Ahmad, Vance G. Fowler, and Thomas L. Holland. “Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia.” Clin Microbiol Infect 29, no. 8 (August 2023): 955–58. https://doi.org/10.1016/j.cmi.2023.04.004.
Mourad A, Fowler VG, Holland TL. Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2023 Aug;29(8):955–8.
Mourad, Ahmad, et al. “Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia.” Clin Microbiol Infect, vol. 29, no. 8, Aug. 2023, pp. 955–58. Pubmed, doi:10.1016/j.cmi.2023.04.004.
Mourad A, Fowler VG, Holland TL. Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2023 Aug;29(8):955–958.
Published In
Clin Microbiol Infect
DOI
EISSN
1469-0691
Publication Date
August 2023
Volume
29
Issue
8
Start / End Page
955 / 958
Location
England
Related Subject Headings
- Staphylococcus aureus
- Staphylococcal Infections
- Microbiology
- Methicillin-Resistant Staphylococcus aureus
- Humans
- High-Throughput Nucleotide Sequencing
- Bacteremia
- Anti-Bacterial Agents
- 3207 Medical microbiology
- 3202 Clinical sciences